Analysts Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Price Target at $490.96

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has received an average rating of “Moderate Buy” from the twenty-seven research firms that are presently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and twenty-two have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $490.9604.

ALNY has been the topic of several recent research reports. Raymond James Financial reaffirmed an “outperform” rating and set a $472.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. JPMorgan Chase & Co. lowered their price objective on Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a research report on Monday, October 13th. Stifel Nicolaus lifted their price objective on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Bank of America decreased their target price on shares of Alnylam Pharmaceuticals from $530.00 to $529.00 and set a “buy” rating for the company in a research report on Monday, January 12th. Finally, Jefferies Financial Group lowered their price target on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a report on Thursday, October 30th.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Pushkal Garg sold 1,510 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $547,933.70. Following the transaction, the executive vice president owned 22,511 shares in the company, valued at $8,168,566.57. The trade was a 6.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Yvonne Greenstreet sold 15,650 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $453.69, for a total transaction of $7,100,248.50. Following the sale, the chief executive officer directly owned 65,409 shares in the company, valued at $29,675,409.21. This trade represents a 19.31% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 56,955 shares of company stock valued at $24,072,733 over the last three months. 1.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock worth $6,185,846,000 after buying an additional 268,313 shares in the last quarter. Capital Research Global Investors lifted its position in shares of Alnylam Pharmaceuticals by 0.4% during the 3rd quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company’s stock valued at $3,293,516,000 after acquiring an additional 31,184 shares during the period. Groupama Asset Managment lifted its position in shares of Alnylam Pharmaceuticals by 160.4% during the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after acquiring an additional 2,483,697 shares during the period. Geode Capital Management LLC boosted its stake in Alnylam Pharmaceuticals by 3.3% during the second quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock worth $779,857,000 after acquiring an additional 75,936 shares in the last quarter. Finally, Orbis Allan Gray Ltd grew its holdings in Alnylam Pharmaceuticals by 29.8% in the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after purchasing an additional 486,489 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $359.27 on Thursday. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. Alnylam Pharmaceuticals has a 52 week low of $205.87 and a 52 week high of $495.55. The firm has a market cap of $47.46 billion, a PE ratio of 1,496.96 and a beta of 0.32. The firm’s fifty day moving average is $418.74 and its 200-day moving average is $422.05.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.